Description: ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Home Page: immucell.com
56 Evergreen Drive
Portland,
ME
04103
United States
Phone:
207 878 2770
Officers
Name | Title |
---|---|
Mr. Michael F. Brigham | President, CEO, Principal Financial Officer, Treasurer, Secretary & Director |
Ms. Bobbi Jo Brockmann | VP of Sales & Marketing and Director |
Ms. Elizabeth L. Williams | Vice President of Manufacturing Operations |
Ms. Elizabeth S. Toothaker | Director of Finance & Administration and Controller |
Mr. A. Gustavo Scaffa | Senior Director of Quality |
John W. Zinckgraf | Director of Product Development |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 1.5358 |
Price-to-Sales TTM: | 1.6501 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 75 |